Tumour necrosis factor-related apoptosis-inducing ligand and osteoprotegerin serum levels in psoriatic arthritis

Rheumatology

Volumn 45, Issue 10, 2006, Pages 1218-1222

  Hofbauer, Lorenz C ^a   Schoppet, M ^a,d   Christ, M ^a,e   Teichmann, J ^b   Lange, U ^c  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b City Hospital   (United Kingdom)

^c JUSTUS LIEBIG UNIVERSITY   (Germany)

^d ADDENBROOKE S HOSPITAL   (United Kingdom)

^e UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Bone metabolism; Inflammatory arthritis; Osteoprotegerin; Psoriatic arthritis; Tumour necrosis factor related apoptosis inducing ligand

Indexed keywords

BIOCHEMICAL MARKER; C REACTIVE PROTEIN; CALCIUM; OSTEOPROTEGERIN; THYROTROPIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADULT; AGED; APOPTOSIS; ARTICLE; BONE DENSITY; BONE METABOLISM; BONE MINERAL; BONE TURNOVER; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; DUAL ENERGY X RAY ABSORPTIOMETRY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FEMUR NECK; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; OSTEOLYSIS; OSTEOPENIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSORIATIC ARTHRITIS; THYROTROPIN BLOOD LEVEL;

ABSORPTIOMETRY, PHOTON; ADULT; AGED; ARTHRITIS, PSORIATIC; BIOLOGICAL MARKERS; BLOOD SEDIMENTATION; BONE DENSITY; BONE DISEASES, METABOLIC; BONE REMODELING; DENSITOMETRY, X-RAY; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; OSTEOPROTEGERIN; STATISTICS, NONPARAMETRIC; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 33749615352     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kel108     Document Type: Article

References (26)

1. Harrison BJ, Hutchinson CE, Adams J, Bruce IN, Herrick AL. Assessing periarticular bone mineral density in patients with early psoriatic arthritis or rheumatoid arthritis. Ann Rheum Dis 2002; 61:1007-11.
2. Millard TP, Antoniades L, Evans AV, Smith HR, Spector TD, Barker JN. Bone mineral density of patients with chronic plaque psoriasis. Clin Exp Dermatol 2001;26:446-8.
3. Frediani B, Allegri A, Falsetti P et al. Bone mineral density in patients with psoriatic arthritis. J Rheumatol 2001;28:138-43.
4. Reid DM, Kennedy NS, Nicoll J, Smith MA, Tothill P, Nuki G. Total and peripheral bone mass in patients with psoriatic arthritis and rheumatoid arthritis. Clin Rheumatol 1986;5:372-8.
5. Zonneveld IM, Bakker WK, Dijkstra PF, Bos JD, van Soesbergen RM, Dinant HJ. Methotrexate osteopathy in long-term, low-dose methotrexate treatment for psoriasis and rheumatoid arthritis. Arch Dermatol 1996;132:184-7.
6. Walsh NC, Gravallese EM. Bone loss in inflammatory arthritis: Mechanisms and treatment strategies. Curr Opin Rheumatol 2004; 16:419-27.
7. Ritchlin CT, Haas-Smith SA, Li P, Hicks DG, Schwarz EM. Mechanisms of TNF-α- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 2003; 111:821-31.
8. Simonet WS, Lacey DL, Dunstan CR et al. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-19.
9. Lacey DL, Timms E, Tan HL et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-76.
10. Kong YY, Feige U, Sarosi I et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999;402:304-9.
11. Emery JG, McDonnell P, Burke MB et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998; 273:14 363-7.
12. Chen GY, He JQ, Lu GC et al. Association between TRAIL expression on peripheral blood lymphocytes and liver damage in chronic hepatitis B. World J Gastroenterol 2005;11:4090-3.
13. Rus V, Zernetkina V, Puliaev R, Cudrici C, Mathai S, Via CS. Increased expression and release of functional tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) by T cells from lupus patients with active disease. Clin Immunol 2005;117:48-56.
14. Michowitz Y, Goldstein E, Roth A et al. The involvement of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in atherosclerosis. J Am Coll Cardiol 2005;45:1018-24.
15. Lub-de Hooge MN, de Vries EG, de Jong S, Bijl M. Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosus. Ann Rheum Dis 2005;64:854-8.
16. Song CJ, Liu XS, Zhu Y et al. Expression of TRAIL, DR4, and DR5 in kidney and serum from patients receiving renal transplantation. Transplant Proc 2004;36:1340-3.
17. Schoppet M, Ruppert V, Hofbauer LC et al. TNF-related apoptosis-inducing ligand and its decoy receptor osteoprotegerin in nonischemic dilated cardiomyopathy. Biochem Biophys Res Commun 2005;338:1745-50.
18. Franck H, Meurer T, Hofbauer LC. Evaluation of bone mineral density, hormones, biochemical markers of bone metabolism, and osteoprotegerin serum levels in patients with ankylosing spondylitis. J Rheumatol 2004;31:2236-41.
19. Rogers A, Eastell R. Circulating osteoprotegerin and receptor activator for nuclear factor κB ligand: Clinical utility in metabolic bone disease assessment. J Clin Endocrinol Metab 2005;90:6323-31.
20. Taylor WJ, Helliwell PS, Gladman DD et al. A validation of current classification criteria for the diagnosis of psoriatic arthritis preliminary results of the CASPAR study. Ann Rheum Dis 2005; 64(Suppl. III):107.
21. Schoppet M, Sattler AM, Schaefer JR, Hofbauer LC. Osteoprotegerin (OPG) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) levels in atherosclerosis. Atherosclerosis 2006;184:446-7.
22. Hofbauer LC, Schoppet M, Schuller P, Viereck V, Christ M. Effects of oral contraceptives on circulating osteoprotegerin and soluble RANK ligand serum levels in healthy young women. Clin Endocrinol 2004;60:214-9.
23. Grisar J, Bernecker PM, Aringer M et al. Ankylosing spondylitis, psoriatic arthritis, and reactive arthritis show increased bone resorption, but differ with regard to bone formation. J Rheumatol 2002;29:1430-6.
24. Jo M, Kim TH, Seol DW et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 2000;6:564-7.
25. Song K, Chen Y, Goke R et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression. J Exp Med 2000;191: 1095-104.
26. Yao Q, Wang S, Gambotto A et al. Intra-articular adenoviral-mediated gene transfer of TRAIL induces apoptosis of arthritic rabbit synovium. Gene Ther 2003;10:1055-60.